Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease

Identifieur interne : 001A85 ( PascalFrancis/Curation ); précédent : 001A84; suivant : 001A86

The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease

Auteurs : Kazuo Yamashiro [Japon] ; Miki Komine-Kobayashi [Japon] ; Taku Hatano [Japon] ; Takao Urabe [Japon] ; Hideki Mochizuki [Japon] ; Nobutaka Hattori [Japon] ; Yoshitaka Iwama [Japon] ; Hiroyuki Daida [Japon] ; Michi Sakai [Japon] ; Takeo Nakayama [Japon] ; Yoshikuni Mizuno [Japon]

Source :

RBID : Pascal:08-0305148

Descripteurs français

English descriptors

Abstract

To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.
pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 23
A06       @2 7
A08 01  1  ENG  @1 The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease
A11 01  1    @1 YAMASHIRO (Kazuo)
A11 02  1    @1 KOMINE-KOBAYASHI (Miki)
A11 03  1    @1 HATANO (Taku)
A11 04  1    @1 URABE (Takao)
A11 05  1    @1 MOCHIZUKI (Hideki)
A11 06  1    @1 HATTORI (Nobutaka)
A11 07  1    @1 IWAMA (Yoshitaka)
A11 08  1    @1 DAIDA (Hiroyuki)
A11 09  1    @1 SAKAI (Michi)
A11 10  1    @1 NAKAYAMA (Takeo)
A11 11  1    @1 MIZUNO (Yoshikuni)
A14 01      @1 Department of Neurology, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.
A14 02      @1 Department of Cardiology, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 7 aut. @Z 8 aut.
A14 03      @1 Department of Health Informatics, Kyoto University School of Public Health @2 Kyoto @3 JPN @Z 9 aut. @Z 10 aut.
A14 04      @1 Research Institute for diseases of Old Age, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 11 aut.
A20       @1 935-941
A21       @1 2008
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000200276040020
A44       @0 0000 @1 © 2008 INIST-CNRS. All rights reserved.
A45       @0 25 ref.
A47 01  1    @0 08-0305148
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.
C02 01  X    @0 002B17
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Insuffisance valvulaire @5 01
C03 01  X  ENG  @0 Valvular regurgitation @5 01
C03 01  X  SPA  @0 Insuficiencia valvular @5 01
C03 02  X  FRE  @0 Cardiopathie valvulaire @5 02
C03 02  X  ENG  @0 Cardiac valvular disease @5 02
C03 02  X  SPA  @0 Cardiopatía valvular @5 02
C03 03  X  FRE  @0 Maladie de Parkinson @2 NM @5 03
C03 03  X  ENG  @0 Parkinson disease @2 NM @5 03
C03 03  X  SPA  @0 Parkinson enfermedad @2 NM @5 03
C03 04  X  FRE  @0 Pathologie du système nerveux @5 04
C03 04  X  ENG  @0 Nervous system diseases @5 04
C03 04  X  SPA  @0 Sistema nervioso patología @5 04
C03 05  X  FRE  @0 Stimulant dopaminergique @5 09
C03 05  X  ENG  @0 Dopamine agonist @5 09
C03 05  X  SPA  @0 Estimulante dopaminérgico @5 09
C07 01  X  FRE  @0 Pathologie de l'appareil circulatoire @5 37
C07 01  X  ENG  @0 Cardiovascular disease @5 37
C07 01  X  SPA  @0 Aparato circulatorio patología @5 37
C07 02  X  FRE  @0 Pathologie de l'encéphale @5 38
C07 02  X  ENG  @0 Cerebral disorder @5 38
C07 02  X  SPA  @0 Encéfalo patología @5 38
C07 03  X  FRE  @0 Syndrome extrapyramidal @5 39
C07 03  X  ENG  @0 Extrapyramidal syndrome @5 39
C07 03  X  SPA  @0 Extrapiramidal síndrome @5 39
C07 04  X  FRE  @0 Maladie dégénérative @5 40
C07 04  X  ENG  @0 Degenerative disease @5 40
C07 04  X  SPA  @0 Enfermedad degenerativa @5 40
C07 05  X  FRE  @0 Pathologie du système nerveux central @5 41
C07 05  X  ENG  @0 Central nervous system disease @5 41
C07 05  X  SPA  @0 Sistema nervosio central patología @5 41
N21       @1 189
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:08-0305148

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</title>
<author>
<name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Komine Kobayashi, Miki" sort="Komine Kobayashi, Miki" uniqKey="Komine Kobayashi M" first="Miki" last="Komine-Kobayashi">Miki Komine-Kobayashi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Urabe, Takao" sort="Urabe, Takao" uniqKey="Urabe T" first="Takao" last="Urabe">Takao Urabe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Iwama, Yoshitaka" sort="Iwama, Yoshitaka" uniqKey="Iwama Y" first="Yoshitaka" last="Iwama">Yoshitaka Iwama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Daida, Hiroyuki" sort="Daida, Hiroyuki" uniqKey="Daida H" first="Hiroyuki" last="Daida">Hiroyuki Daida</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Sakai, Michi" sort="Sakai, Michi" uniqKey="Sakai M" first="Michi" last="Sakai">Michi Sakai</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Nakayama, Takeo" sort="Nakayama, Takeo" uniqKey="Nakayama T" first="Takeo" last="Nakayama">Takeo Nakayama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Research Institute for diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">08-0305148</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0305148 INIST</idno>
<idno type="RBID">Pascal:08-0305148</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001234</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001A85</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</title>
<author>
<name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Komine Kobayashi, Miki" sort="Komine Kobayashi, Miki" uniqKey="Komine Kobayashi M" first="Miki" last="Komine-Kobayashi">Miki Komine-Kobayashi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Urabe, Takao" sort="Urabe, Takao" uniqKey="Urabe T" first="Takao" last="Urabe">Takao Urabe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Iwama, Yoshitaka" sort="Iwama, Yoshitaka" uniqKey="Iwama Y" first="Yoshitaka" last="Iwama">Yoshitaka Iwama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Daida, Hiroyuki" sort="Daida, Hiroyuki" uniqKey="Daida H" first="Hiroyuki" last="Daida">Hiroyuki Daida</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Sakai, Michi" sort="Sakai, Michi" uniqKey="Sakai M" first="Michi" last="Sakai">Michi Sakai</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Nakayama, Takeo" sort="Nakayama, Takeo" uniqKey="Nakayama T" first="Takeo" last="Nakayama">Takeo Nakayama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author>
<name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Research Institute for diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cardiac valvular disease</term>
<term>Dopamine agonist</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Valvular regurgitation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Insuffisance valvulaire</term>
<term>Cardiopathie valvulaire</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>23</s2>
</fA05>
<fA06>
<s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>YAMASHIRO (Kazuo)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>KOMINE-KOBAYASHI (Miki)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>HATANO (Taku)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>URABE (Takao)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>MOCHIZUKI (Hideki)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>HATTORI (Nobutaka)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>IWAMA (Yoshitaka)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>DAIDA (Hiroyuki)</s1>
</fA11>
<fA11 i1="09" i2="1">
<s1>SAKAI (Michi)</s1>
</fA11>
<fA11 i1="10" i2="1">
<s1>NAKAYAMA (Takeo)</s1>
</fA11>
<fA11 i1="11" i2="1">
<s1>MIZUNO (Yoshikuni)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Research Institute for diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20>
<s1>935-941</s1>
</fA20>
<fA21>
<s1>2008</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000200276040020</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>08-0305148</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Insuffisance valvulaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Valvular regurgitation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Insuficiencia valvular</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Cardiopathie valvulaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Cardiac valvular disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Cardiopatía valvular</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Stimulant dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Dopamine agonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Estimulante dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21>
<s1>189</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A85 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001A85 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0305148
   |texte=   The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024